Cargando…
A comparison of four technologies for detecting p53 aggregates in ovarian cancer
The tumor suppressor protein p53 is mutated in half of all cancers and has been described to form amyloid-like structures, commonly known from key proteins in neurodegenerative diseases. Still, the clinical relevance of p53 aggregates remains largely unknown, which may be due to the lack of sensitiv...
Autores principales: | Heinzl, Nicole, Koziel, Katarzyna, Maritschnegg, Elisabeth, Berger, Astrid, Pechriggl, Elisabeth, Fiegl, Heidi, Zeimet, Alain G., Marth, Christian, Zeillinger, Robert, Concin, Nicole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493009/ https://www.ncbi.nlm.nih.gov/pubmed/36158680 http://dx.doi.org/10.3389/fonc.2022.976725 |
Ejemplares similares
-
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011) -
Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer
por: Schmid, Gabriel, et al.
Publicado: (2016) -
Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
por: Leitner, Katharina, et al.
Publicado: (2020) -
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018) -
Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer
por: Azim, Samira Abdel, et al.
Publicado: (2016)